» Articles » PMID: 21322634

Design, Synthesis, and Structure-activity Relationship of Trypanosoma Brucei Leucyl-tRNA Synthetase Inhibitors As Antitrypanosomal Agents

Overview
Journal J Med Chem
Specialty Chemistry
Date 2011 Feb 17
PMID 21322634
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

African trypanosomiasis, caused by the proto zoal pathogen Trypanosoma brucei (T. brucei), is one of the most neglected tropical diseases that are in great need of new drugs. We report the design and synthesis of T. brucei leucyl-tRNA synthetase (TbLeuRS) inhibitors and their structure--activity relationship. Benzoxaborole was used as the core structure and C(6) was modified to achieve improved affinity based on docking results that showed further binding space at this position. Indeed, compounds with C(7) substitutions showed diminished activity due to clash with the eukaryote specific I4ae helix while substitutions at C(6) gave enhanced affinity. TbLeuRS inhibitors with IC(50) as low as 1.6 μM were discovered, and the structure-activity relationship was discussed. The most potent enzyme inhibitors also showed excellent T. brucei parasite growth inhibition activity. This is the first time that TbLeuRS inhibitors are reported, and this study suggests that leucyl-tRNA synthetase (LeuRS) could be a potential target for antiparasitic drug development.

Citing Articles

Approved drugs successfully repurposed against based on machine learning predictions.

Oualha R, Abdelkrim Y, Guizani I, Harigua-Souiai E Front Cell Infect Microbiol. 2024; 14:1403589.

PMID: 39391884 PMC: 11464777. DOI: 10.3389/fcimb.2024.1403589.


Exploiting thiol-functionalized benzosiloxaboroles for achieving diverse substitution patterns - synthesis, characterization and biological evaluation of promising antibacterial agents.

Nowicki K, Krajewska J, Stepniewski T, Wielechowska M, Winska P, Kaczmarczyk A RSC Med Chem. 2024; 15(5):1751-1772.

PMID: 38784477 PMC: 11110727. DOI: 10.1039/d4md00061g.


Aminoacyl tRNA Synthetases: Implications of Structural Biology in Drug Development against Trypanosomatid Parasites.

Nasim F, Qureshi I ACS Omega. 2023; 8(17):14884-14899.

PMID: 37151504 PMC: 10157851. DOI: 10.1021/acsomega.3c00826.


Advances in Protozoan Epigenetic Targets and Their Inhibitors for the Development of New Potential Drugs.

Gaona-Lopez C, Vazquez-Jimenez L, Gonzalez-Gonzalez A, Delgado-Maldonado T, Ortiz-Perez E, Nogueda-Torres B Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111300 PMC: 10143871. DOI: 10.3390/ph16040543.


Oxazoline scaffold in synthesis of benzosiloxaboroles and related ring-expanded heterocycles: diverse reactivity, structural peculiarities and antimicrobial activity.

Krajewska J, Nowicki K, Durka K, Marek-Urban P, Winska P, Stepniewski T RSC Adv. 2022; 12(36):23099-23117.

PMID: 36090419 PMC: 9379557. DOI: 10.1039/d2ra03910a.